Curtana Pharmaceuticals

Curtana Pharmaceuticals was founded with the mission to develop the first truly targeted therapy for treating the most aggressive types of brain cancer in both adults and children. The company’s drug development program is based on the groundbreaking research of Dr. Santosh Kesari, who is currently the Chair of Translational Neuro-Oncology and Neurotherapeutics at the John Wayne Cancer Institute in Santa Monica, California.Curtana’s senior leadership team has extensive experience in the pharmaceutical industry, with a strong background in developing new molecular entities for the treatment of cancer and central nervous system disorders.